Astrocytoma surgery: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Astrocytoma}} | {{Astrocytoma}} | ||
{{CMG}} | |||
==Overview== | |||
===Surgery=== | |||
* A NIH Consensus Conference report in 1999 recommends that any SEGA that is growing or causing symptoms should be surgically removed. Tumors are also removed in cases where a patient is suffering from a high seizure burden. If a tumor is rapidly growing or causing symptoms of [[hydrocephalus]], deferring [[surgery]] may lead to vision loss, need for [[ventricular shunt]], and ultimately [[death]]. Total removal of the [[tumor]] is curative. | |||
* [[Surgery]] to remove [[intraventricular tumor]]s also carries risks of complications or death. Potential complications include transient [[memory]] impairment, [[hemiparesis]], [[infection]], chronic ventriculoperitoneal shunt placement, [[stroke]], and [[death]]. | |||
* Surgery is needed for most primary [[brain]] tumors. Some [[tumor]]s may be completely removed. In cases where the [[tumor]] cannot be removed, surgery may help reduce pressure and relieve symptoms. | |||
* Surgical removal remains the mainstay of treatment for Glioblastoma Multiforme, provided that unacceptable neurologic injury can be avoided. The extremely infiltrative nature of this tumor makes complete surgical removal impossible. | |||
* [[Chemotherapy]] or [[radiation therapy]] may be used for certain tumors.<ref name=tsalliance> | |||
{{cite web| title=Supependymal Giant Cell Tumor (SGCT) or Subependymal Giant Cell Astrocytoma (SEGA)| url=http://www.tsalliance.org/documents/Subependymal%20Giant%20Cell%20Tumor%20SGCT%20or%20Subependymal%20Giant%20Cell%20Astrocytoma%20SEGA.pdf| publisher=Tuberous Sclerosis Alliance| accessdate=9 September 2014| date=June 2006}} | |||
</ref> | |||
<ref name=campen2011> | |||
{{cite journal|last1=Campen|first1=Cynthia J.|last2=Porter|first2=Brenda E.|title=Subependymal Giant Cell Astrocytoma (SEGA) Treatment Update|journal=Current Treatment Options in Neurology|date=August 2011|volume=13|issue=4|pages=380–5|doi=10.1007/s11940-011-0123-z|pmid=21465222|pmc=3130084}} | |||
</ref> | |||
==References== | ==References== | ||
Revision as of 18:17, 23 August 2015
|
Astrocytoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Study |
|
Astrocytoma surgery On the Web |
|
American Roentgen Ray Society Images of Astrocytoma surgery |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Surgery
- A NIH Consensus Conference report in 1999 recommends that any SEGA that is growing or causing symptoms should be surgically removed. Tumors are also removed in cases where a patient is suffering from a high seizure burden. If a tumor is rapidly growing or causing symptoms of hydrocephalus, deferring surgery may lead to vision loss, need for ventricular shunt, and ultimately death. Total removal of the tumor is curative.
- Surgery to remove intraventricular tumors also carries risks of complications or death. Potential complications include transient memory impairment, hemiparesis, infection, chronic ventriculoperitoneal shunt placement, stroke, and death.
- Surgery is needed for most primary brain tumors. Some tumors may be completely removed. In cases where the tumor cannot be removed, surgery may help reduce pressure and relieve symptoms.
- Surgical removal remains the mainstay of treatment for Glioblastoma Multiforme, provided that unacceptable neurologic injury can be avoided. The extremely infiltrative nature of this tumor makes complete surgical removal impossible.
- Chemotherapy or radiation therapy may be used for certain tumors.[1]
References
- ↑ "Supependymal Giant Cell Tumor (SGCT) or Subependymal Giant Cell Astrocytoma (SEGA)" (PDF). Tuberous Sclerosis Alliance. June 2006. Retrieved 9 September 2014.
- ↑ Campen, Cynthia J.; Porter, Brenda E. (August 2011). "Subependymal Giant Cell Astrocytoma (SEGA) Treatment Update". Current Treatment Options in Neurology. 13 (4): 380–5. doi:10.1007/s11940-011-0123-z. PMC 3130084. PMID 21465222.